

Niamh M O'connell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5748479/publications.pdf>

Version: 2024-02-01

38
papers

1,689
citations

516561

16
h-index

360920

35
g-index

38
all docs

38
docs citations

38
times ranked

2141
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID19 coagulopathy in Caucasian patients. British Journal of Haematology, 2020, 189, 1044-1049.	1.2	307
2	Guideline for the diagnosis and management of the rare coagulation disorders. British Journal of Haematology, 2014, 167, 304-326.	1.2	266
3	Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. Journal of Thrombosis and Haemostasis, 2021, 19, 1064-1070.	1.9	142
4	Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood, 2003, 101, 4783-4788.	0.6	122
5	Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion, 2003, 43, 1711-1716.	0.8	120
6	Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood, 2017, 130, 2344-2353.	0.6	98
7	Factor XI deficiency. Seminars in Hematology, 2004, 41, 76-81.	1.8	80
8	Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Advances, 2018, 2, 1784-1791.	2.5	79
9	More on COVID-19 coagulopathy in Caucasian patients. British Journal of Haematology, 2020, 189, 1060-1061.	1.2	73
10	Factor XI deficiency database: an interactive web database of mutations, phenotypes, and structural analysis tools. Human Mutation, 2005, 26, 192-198.	1.1	59
11	Factor XI deficiency - from molecular genetics to clinical management. Blood Coagulation and Fibrinolysis, 2003, 14, S59-S64.	0.5	58
12	Analysis and results of the recombinant factor VIIa extended-use registry. Blood Coagulation and Fibrinolysis, 2003, 14, S35-S38.	0.5	50
13	Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors. British Journal of Haematology, 2002, 116, 632-635.	1.2	39
14	Increased galactose expression and enhanced clearance in patients with low von Willebrand factor. Blood, 2019, 133, 1585-1596.	0.6	32
15	Telehealth for delivery of haemophilia comprehensive care during the COVID-19 pandemic. Haemophilia, 2020, 26, 984-990.	1.0	31
16	Allogeneic Hematopoietic Stem Cell Transplantation for aBCR-FGFR1 Myeloproliferative Neoplasm Presenting as Acute Lymphoblastic Leukemia. Case Reports in Hematology, 2012, 2012, 1-5.	0.3	17
17	Total Knee Arthroplasty in Hemophilia: Survivorship and Outcomes—A Systematic Review and Meta-Analysis. Journal of Arthroplasty, 2022, 37, 581-592.e1.	1.5	13
18	A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen. Haemophilia, 2021, 27, 544-562.	1.0	12

#	ARTICLE	IF	CITATIONS
19	First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies. <i>Blood</i> , 2020, 136, LBA-6-LBA-6.	0.6	11
20	Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. <i>Haemophilia</i> , 2021, 27, 221-228.	1.0	10
21	Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort. <i>Haemophilia</i> , 2021, 27, 618-625.	1.0	9
22	Clinical conditions and patient factors significantly influence diagnostic utility of D-dimer in venous thromboembolism. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 244-247.	0.5	7
23	The current and future role of plasma-derived clotting factor concentrate in the treatment of haemophilia A. <i>Transfusion and Apheresis Science</i> , 2018, 57, 502-506.	0.5	7
24	Management of elective procedures in low von Willebrand factor patients in the LoVIC study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 701-710.	1.9	7
25	Single centre, real-world experience of perioperative rFIXFc use in adult patients with haemophilia B undergoing major and minor surgery. <i>Haemophilia</i> , 2021, 27, e690-e697.	1.0	7
26	The patients' perspective of international normalized ratio self-testing, remote communication of test results and confidence to move to self-management. <i>Journal of Clinical Nursing</i> , 2017, 26, 4379-4389.	1.4	6
27	Out of Sight, out of Mind? An Audit Which Proposes a Follow-Up and Management Pathway for Inferior Vena Cava Filters. <i>Thrombosis</i> , 2016, 2016, 1-3.	1.4	5
28	Missed at first Glanz: Glanzmann thrombasthenia initially misdiagnosed as Von Willebrand Disease. <i>Transfusion and Apheresis Science</i> , 2019, 58, 58-60.	0.5	5
29	Management of combined factor V and factor VIII deficiency in pregnancy. <i>Journal of Obstetrics and Gynaecology</i> , 2019, 39, 271-272.	0.4	4
30	Recombinant factor IX Fc fusion protein in severe hemophilia B: Patient-reported outcomes and health-related quality of life. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12602.	1.0	4
31	Enhanced VWF clearance in low VWF pathogenesis: limitations of the VWFpp/VWF:Ag ratio and clinical significance. <i>Blood Advances</i> , 2023, 7, 302-308.	2.5	3
32	Novel Insights into the Clinical Phenotype and Pathophysiology Underlying Low VWF Levels: The Low Von Willebrand Factor in Ireland Cohort (LoVIC) Study. <i>Blood</i> , 2016, 128, 873-873.	0.6	2
33	A 5-day: the favourable way?. <i>Annals of Hematology</i> , 2014, 93, 1619-1620.	0.8	1
34	A 5-day outpatient regimen of azacitidine is effective and well tolerated in patients with acute myeloid leukemia unsuitable for intensive chemotherapy. <i>Leukemia and Lymphoma</i> , 2014, 55, 2950-2951.	0.6	1
35	Bleeding Outcomes in People with Von Willebrand Disease Receiving Antithrombotic Therapy. <i>Blood</i> , 2021, 138, 3196-3196.	0.6	1
36	Changing paradigms of hemophilia care across larger specialized treatment centers in the European region. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210884.	1.1	1

#	ARTICLE	IF	CITATIONS
37	The Low Von Willebrand Factor in Ireland Cohort Study - Defining Optimal Management for Procedures in Patients with Low VWF (30-50 IU/dL). <i>Blood</i> , 2018, 132, 1178-1178.	0.6	0
38	The Irish Personalized Approach to the Treatment of Haemophilia (iPATH) - Determinants of Inter-Individual Variation in FVIII Pharmacokinetics. <i>Blood</i> , 2018, 132, 1190-1190.	0.6	0